As analysts and investors digested the implications of the colossal combination of Gilead Sciences Inc. and Pharmasset Inc. on the hepatitis C virus (HCV) market, some began to speculate on the logical next question: What comes next? Read More
Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept) hits the market this week, and analysts are looking to its less frequent dosing schedule and lower cost to nab a substantial portion of the market from Roche AG's reigning VEGF inhibitors – Lucentis (ranibizumab) and cheaper off-label cancer drug Avastin (bevacizumab) – in wet age-related macular degeneration (AMD). Read More
Having raised $89 million in its latest financing round, Portola Pharmaceuticals Inc. is preparing to fly solo on its pivotal Phase III trial that will evaluate betrixaban in the prevention of pulmonary embolisms. Read More
Chronic wounds are a major source of morbidity, particularly for patients who are elderly, diabetic or who have multiple medical problems. The standard of care for treating such wounds, particularly foot ulcers, results in complete healing in only 33 percent of the patients. Read More
• Dendreon Corp., of Seattle, said that under an updated coverage policy, the Centers for Medicare & Medicaid Services (CMS) will now cover the infusion costs associated with the administration of Provenge (sipuleucel-T). Read More
• Celldex Therapeutics Inc., of Needham, Mass., presented Phase II data showing rindopepimut (CDX-110) resulted in final overall survival of 24.6 months from diagnosis of EGFRvIII-positive glioblastoma, compared to 15.2 months for a historic control. Read More
